MRNA’s 5.4% drop doesn’t make it deep value

I don’t know what caused today’s −5.41% move, and it does not change my view: MRNA still is not a deep-value entry. The Q3 result was encouraging—revenue rose 30.9% to $1,312M and EPS was $0.38 versus an estimated loss of $1.255—but one profitable quarter does not establish durable cash generation. Free cash flow was −$1,680M, debt/equity increased to 0.62, and consensus still estimates losses of $7.371 per share in 2026 and $4.338 in 2027. At $235.25, the shares are only 12.5% below their 52-week high after gaining 790.7% in 12 months; the median analyst target is $125. The pullback may be a normal reversal after that rally, not a compelling bargain. I stay out and keep my cash available.